Catalyst
Slingshot members are tracking this event:
Ionis Pharma (IONS) to complete Phase 2a study of ISIS 463588 (ISIS-FGFR4RX) in Obese Patients in 2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| IONS |
|
|
||||
Additional Information
- Estimated Enrollment:12
- Study Start Date:June 2015
- Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
- Estimated Study Completion Date: October 2016
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 07, 2017
Occurred Source:
https://clinicaltrials.gov/archive/NCT02476019/2017_02_07/changes
Related Projects
- What Does the Future Hold for Ionis Pharma’s Obesity Drug FGFR4Rx with Phase 2a Nearing Completion? IONS Execute By: Nov 22, 2016
Related Keywords
Obesity, Phase 2a Study, Isis 463588, Isis-fgfr4rx
